June 12, 2026 • 19 mins
Your medicine cabinet feels organized for a reason: we like to believe each pill has a single target and stays in its lane. Then we hit a finding that blows up that mental map. Millions of people take statins and other cholesterol drugs to manage LDL and cardiovascular risk, but a massive new dataset suggests those same lipid-lowering regimens may also slow Alzheimer’s disease decline, especially in the years when independence matters most.
We walk through a 2026 study drawing on more than 28,000 participants followed for up to 15 years, and we explain why the first glance at the data looks scary. Statin users score worse at baseline on common cognitive tests, yet that’s the classic trap of confounding by indication: the people on the meds start out with higher vascular and metabolic risk. When the researchers focus on longitudinal change using a real-world functional scale, the trend flips. Small annual differences compound, lowering transition rates from mild cognitive impairment to dementia and slowing progression even in later stages.
Then comes the twist: autopsy data shows no meaningful difference in classic Alzheimer’s pathology measures between users and non-users. That forces a new frame centered on systemic resilience. We connect vascular stabilization, anti-inflammatory effects, and a specific biochemical culprit: oxysterols like 27OHC that can cross the blood-brain barrier, overstimulate microglia, and accelerate neuroinflammation. We also dig into who sees the biggest benefits by age, sex, and APOE4 genetics, and we end with a provocative question about next-generation drugs designed to act inside the brain. Subscribe, share this with someone thinking about brain health, and leave a review with the question you want us to tackle next.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_00 (00:00):
So, um when you open your medicine cabinet every
morning, you likely have this,you know, ingrained expectation
of geography.
SPEAKER_01 (00:09):
Aaron Powell Oh, absolutely.
You assume every little bottlehas its own strictly assigned
territory.
SPEAKER_00 (00:13):
Aaron Powell Right.
Like the white pill works onyour heart, the blue one goes to
your lungs, and you know, neverthe twain shall meet.
SPEAKER_01 (00:20):
Yeah, which is a very compartmentalized way of
thinking about human biology.
I mean, it's completelyunderstandable, but it's uh it's
fundamentally inaccurate.
SPEAKER_00 (00:28):
Totally.
SPEAKER_01 (00:29):
Because the body is this immensely complex
interconnected network.
So a drug engineered for onespecific organ is often quietly
remodeling an entirely differentsystem at the exact same time.
SPEAKER_00 (00:40):
Aaron Ross Powell, which is exactly why a
medication millions of peopletake simply to lower their
cholesterol might actually be uma critical key to slowing down
Alzheimer's disease.
SPEAKER_01 (00:50):
Aaron Powell Yeah, it's a fascinating connection.
SPEAKER_00 (00:52):
Aaron Powell So today we're doing a deep dive
for you into a massive new studypublished in 2026 in the Journal
of Prevention of Alzheimer'sdisease.
SPEAKER_01 (00:59):
Right by Sternberg and colleagues.
SPEAKER_00 (01:01):
Aaron Powell Exactly.
And our mission for this deepdive is to bridge that gap.
We want to connect the everydaylipid lowering regimens, you
know, standard statins andcholesterol drugs, with the
actual physical architecture ofthe brain.
SPEAKER_01 (01:14):
Aaron Powell And I think what makes this research
so definitive is the sheer scaleof the data Sternberg's team
utilized.
SPEAKER_00 (01:21):
Oh wow.
Yeah, let's unpack that.
Yeah.
Because they didn't just look ata few hundred people over a
semester or something.
SPEAKER_01 (01:26):
No, not at all.
They pulled records for over28,000 participants from the
National Alzheimer'sCoordinating Center.
SPEAKER_00 (01:32):
Aaron Powell That is massive.
SPEAKER_01 (01:34):
It really is.
And they tracked theseindividuals for up to 15 years.
SPEAKER_00 (01:38):
Aaron Powell A decade and a half of tracking
human lives.
But you know, to get a cleansignal from all that messy data,
they had to be pretty ruthlesswith their filtering, right?
SPEAKER_01 (01:47):
Aaron Ross Powell They were incredibly ruthless.
They ingeniously excluded anyonetaking blood pressure or
diabetes medications.
SPEAKER_00 (01:52):
Aaron Powell Wait, why just those two?
SPEAKER_01 (01:54):
Aaron Powell Well, we know hypertension and insulin
resistance heavily influencecognitive decline on their own.
SPEAKER_00 (01:59):
Aaron Powell Ah, right.
It muddies the waters.
SPEAKER_01 (02:01):
Aaron Ross Powell Exactly.
So by removing participants onthose specific treatments, the
researchers essentially strippedaway the overlapping noise.
SPEAKER_00 (02:09):
Aaron Powell Okay.
So they isolated the exactindependent effect of the
cholesterol drugs to see whatthey were doing on their own.
SPEAKER_01 (02:15):
Aaron Powell That's it.
But you know what's fascinatinghere is that the findings don't
actually start with a triumph.
SPEAKER_00 (02:21):
Aaron Powell No, they really don't.
In fact, if you just glance atthe initial cross-sectional data
like the day zero snapshot ofall these participants, it
creates a pretty alarmingpicture.
Trevor Burrus, Jr.
SPEAKER_01 (02:32):
It does.
It looks terrible at firstglance.
SPEAKER_00 (02:34):
Aaron Powell Because the participants taking the
cholesterol drugs were actuallyscoring worse on cognitive tests
compared to the people nottaking the medication.
SPEAKER_01 (02:42):
Trevor Burrus Right.
The initial data showedsignificantly lower scores on
the MOCA.
SPEAKER_00 (02:46):
That's the Montreal cognitive assessment.
SPEAKER_01 (02:48):
Yes, exactly.
It's used to check short-termmemory and uh visuospatial
abilities.
And they also scored lower onthe MMSE.
SPEAKER_00 (02:55):
Aaron Powell The Mini Mental State Examination.
Trevor Burrus, Jr.
SPEAKER_01 (02:57):
Right, which measures basic orientation and
attention.
SPEAKER_00 (02:59):
Aaron Ross Powell So seeing that on a spreadsheet
immediately triggers a bias.
I mean you see a group of peopletaking a specific pill, and you
see that they have worse memoryscores.
SPEAKER_01 (03:08):
Aaron Powell Yeah.
The instinct is to assume themedication is causing the
decline.
SPEAKER_00 (03:12):
Aaron Powell Wait, so does that mean the medicine
is compromising their cognition?
I mean it's the classic logicalfallacy of walking into a
hospital, seeing rows of sickpeople in beds, and concluding
that the hospital buildingitself is making them sick.
SPEAKER_01 (03:27):
Aaron Powell That's a great analogy.
And that phenomenon is known inepidemiology as confounding by
indication.
SPEAKER_00 (03:33):
Aaron Powell Confounding by Indication.
Okay, break that down for us.
SPEAKER_01 (03:36):
Aaron Ross Powell Well, we have to look at the
underlying reason theseparticipants were prescribed
lipid lowering regimens in thefirst place.
SPEAKER_00 (03:42):
Aaron Powell They got high cholesterol.
SPEAKER_01 (03:43):
Exactly.
They had existing vascularissues.
Their baseline cardiovascularand metabolic risk profiles were
significantly worse than thecontrol group.
SPEAKER_00 (03:52):
Aaron Powell So their underlying biology had
already put them in the dangerzone for cognitive decline long
before the study even started.
SPEAKER_01 (03:58):
Aaron Powell Precisely.
Chronic high cholesterol subtlydamages the microvessels
throughout the body.
And that includes the tiny bloodvessels supplying the brain.
Right.
So the people taking themedication were inherently more
vulnerable to cognitive issuesright from the start.
SPEAKER_00 (04:14):
Aaron Powell So that initial cross-sectional
snapshot, it merely captures thereality that sicker people
require more medication.
SPEAKER_01 (04:21):
Exactly.
To strip away that bias, we haveto look past the snapshot and
analyze the longitudinal dataover time.
You know, the 10-year movie.
SPEAKER_00 (04:30):
Okay, let's unpack that longitudinal data because
the 10-year progressioncompletely flips the script.
SPEAKER_01 (04:35):
It really does.
It's a dramatic shift.
SPEAKER_00 (04:37):
Aaron Powell So the researchers tracked cognitive
and functional decline using theCDR SOB.
That's the clinical dementiarating sum of boxes.
SPEAKER_01 (04:45):
Aaron Powell Right, which is a scoring system that
moves beyond just, you know,standard memory quizzes.
SPEAKER_00 (04:49):
Aaron Powell It measures real-world functional
decline, right?
Things like personal care,community affairs, and problem
solving.
SPEAKER_01 (04:55):
Aaron Powell Yes, exactly.
It's about how someone actuallynavigates their life.
And for participants who startedthe study with mild cognitive
impairment, the users of thecholesterol drugs experienced a
noticeably slower rate ofdecline.
SPEAKER_00 (05:08):
Aaron Powell Okay, but let's look at the actual
numbers.
Because the data showed theiryearly increase on that dementia
severity scale was reduced by0.0088 units compared to
non-users.
SPEAKER_01 (05:21):
Aaron Powell That is what the data showed, yes.
SPEAKER_00 (05:23):
I have to play the skeptic here because
mathematically, point zero zerozero eight eight sounds entirely
negligible.
I mean, why should you or I careabout a fraction of a fraction
of a point?
SPEAKER_01 (05:33):
I get that.
It sounds tiny in a vacuum.
SPEAKER_00 (05:36):
Right.
It's hard to see the practicalvalue.
SPEAKER_01 (05:38):
But chronic neurodegeneration is a game of
inches.
You have to conceptualize thisin the context of a progressive
disease that currently has nodefinitive cure.
Aaron Ross Powell, Jr.
SPEAKER_00 (05:46):
Buying time is the ultimate clinical goal.
SPEAKER_01 (05:49):
Exactly.
Alzheimer's doesn't strip awayindependence overnight.
It's a gradual cascadingfailure.
SPEAKER_00 (05:54):
Aaron Ross Powell So it's the physiological
equivalent of compoundinginterest.
SPEAKER_01 (05:57):
That's a perfect way to look at it.
SPEAKER_00 (05:58):
Like if you shift an interest rate by a fraction of a
percent when you open aretirement account, the
difference year over year isinvisible.
SPEAKER_01 (06:05):
Right.
You don't notice it in year oneor two.
SPEAKER_00 (06:07):
But let that tiny mathematical change compound
over a decade, and it creates amassive divergence in the final
outcome.
SPEAKER_01 (06:15):
Aaron Powell And that divergence is clearly
visible in the transition rates.
So among those with mildcognitive impairment, only 1.48%
of the cholesterol drug userstransitioned into full-blown
dementia per year.
SPEAKER_00 (06:29):
Compared to 1.83% of the non-users.
SPEAKER_01 (06:32):
Yes.
And over 10 years, thatfractional difference compounds
into literally years ofpreserved daily function.
SPEAKER_00 (06:40):
Oh wow.
So it represents the differencebetween an individual managing
their own household versusrequiring institutionalized
round-the-clock care.
SPEAKER_01 (06:49):
Absolutely.
It's the difference betweenliving at home and being in a
nursing facility.
SPEAKER_00 (06:52):
And the protection also held for people already
suffering from advanced stagesof the disease, didn't it?
SPEAKER_01 (06:57):
It did.
For participants who had alreadyprogressed to dementia, the
slowing effect was actually evenmore pronounced.
SPEAKER_00 (07:03):
Wait, really?
Even in late stages?
SPEAKER_01 (07:05):
Yeah.
Over a 10-year window, only0.53% of the lipid-lowering drug
users hit the severe final stageof dementia.
SPEAKER_00 (07:13):
Compared to 1.50% of the non-users, that is a massive
relative difference.
SPEAKER_01 (07:18):
Aaron Powell It's huge.
And over the full 15-yeartracking period, the drug users
simply survived significantlylonger.
SPEAKER_00 (07:24):
Aaron Powell Okay, so we know the drugs by time,
but do they via the same amountof time for everyone?
SPEAKER_01 (07:30):
That is a great question.
And the demographicstratification of this data is
where we find the realmechanical insights.
SPEAKER_00 (07:36):
Aaron Powell Because this protective effect was not
universally distributed acrossthe population.
SPEAKER_01 (07:41):
Rare.
No, it wasn't.
The age breakdown isparticularly fascinating.
Aaron Powell Yeah.
SPEAKER_00 (07:45):
The study showed the protective benefits only emerge
in participants over the age of50.
Trevor Burrus, Jr.
SPEAKER_01 (07:49):
Right.
If a participant was in theirforties, the cholesterol drugs
showed essentially no cognitivebenefit whatsoever.
SPEAKER_00 (07:55):
Trevor Burrus And the protection was strongest for
those over 70.
Trevor Burrus, Jr.
SPEAKER_01 (07:57):
Which aligns perfectly with how cumulative
biological damage works.
I mean, a 40-year-old braingenerally still has robust
vascular defenses andneuroplasticity.
SPEAKER_00 (08:06):
Aaron Powell So the structural damage from poor
lipid metabolism hasn't reacheda critical threshold yet.
SPEAKER_01 (08:12):
Exactly.
But by age 70, the cumulativevascular and metabolic stress is
actively threatening the brain'sdefenses.
SPEAKER_00 (08:19):
So the medication is intervening exactly when the
biological infrastructure beginsto buckle.
SPEAKER_01 (08:24):
You hit the nail on the head.
And then there is a geneticlayer specifically regarding the
APOE4 allele.
SPEAKER_00 (08:30):
Right.
We've long known that carryingthe APOE4 gene is one of the
most significant risk factorsfor developing Alzheimer's.
SPEAKER_01 (08:36):
Yes, it's a major genetic red flag.
SPEAKER_00 (08:38):
And the study found that people with this specific
genetic marker saw highlypronounced outsized benefits
from taking these cholesteroldrugs.
SPEAKER_01 (08:46):
To understand why, we have to look at what APOE4
actually does.
SPEAKER_00 (08:50):
Okay, lay it on this.
SPEAKER_01 (08:51):
So the APOE gene family produces apalipoprotein
E.
This is a protein thattransports fats and cholesterol
throughout the body and thebrain.
Right.
But the E4 variant of this geneis structurally less efficient.
It struggles to clear lipids,leading to cellular stress and
inflammation.
SPEAKER_00 (09:07):
Wait, so the gene most famous for causing
Alzheimer's, it's fundamentallya cholesterol management gene.
SPEAKER_01 (09:12):
Yes, exactly.
If we connect this to the biggerpicture, when a patient with
that faulty E4 gene takes alipid-lowering drug, the
medication is actively reducingthe overall peripheral
cholesterol burden.
SPEAKER_00 (09:25):
Oh, I see.
It is artificially managing thelipid load that the genetic
mutation is failing to handle.
SPEAKER_01 (09:31):
Precisely.
It provides direct support tothe exact biological system, the
APOE4 mutation compromises.
SPEAKER_00 (09:38):
So what does this all mean?
It makes me think of puttingpremium fuel into a car engine.
SPEAKER_01 (09:43):
Oh, I like where this is going.
SPEAKER_00 (09:45):
Like if you have a brand new low-risk engine, say,
a 40-year-old without the APOE4gene paying for premium fuel
doesn't noticeably change howthe car dries.
SPEAKER_01 (09:55):
Right.
The engine is already highlyefficient.
SPEAKER_00 (09:57):
But if the engine is older, or if it has a faulty
fuel injector that causes it torun hot, which is essentially
what the APOE4 gene is doing,suddenly that premium fuel makes
a massive difference inpreventing a breakdown on the
highway.
SPEAKER_01 (10:08):
That is a brilliant analogy.
And taking that car analogy astep further, the researchers
also uncovered distinctmechanical differences based on
gender.
SPEAKER_00 (10:16):
Oh, right.
For the transition phase, movingfrom mild cognitive impairment
into early dementia men sawsignificant protective benefits
from the medication while womendid not.
SPEAKER_01 (10:27):
Yes, but only in that early transition phase.
SPEAKER_00 (10:30):
Because once the disease progressed into the
later stages of dementia, bothmen and women benefited
significantly.
SPEAKER_01 (10:37):
Right.
And we think this is becausehormonal environments uniquely
influence lipid metabolism andvascular health.
SPEAKER_00 (10:44):
Like estrogen.
SPEAKER_01 (10:45):
Exactly.
Estrogen offers distinctneuroprotective and vascular
benefits early on.
This might mask or alter theeffectiveness of the
lipid-lowering drugs in womenduring that initial transition
phase.
SPEAKER_00 (10:56):
Ah, but once those hormonal protections wane or the
disease pathology overwhelmsthem in later stages, the
benefits of the drugs becomeuniversal.
SPEAKER_01 (11:05):
That's exactly what the data suggests.
SPEAKER_00 (11:06):
Okay, so we've established the demographics,
and the data clearly shows thesedrugs are buying people crucial
years of independence.
SPEAKER_01 (11:12):
Yes, they absolutely are.
SPEAKER_00 (11:13):
Which brings us to the most logical assumption.
If these patients are thinkingclearer, functioning better, and
surviving longer, thesecholesterol drugs must be
actively clearing theAlzheimer's pathology out of
their brains.
SPEAKER_01 (11:27):
It is the most logical assumption to make.
You'd think a slower cognitivedecline should equal a cleaner
brain.
SPEAKER_00 (11:33):
We would expect their brains to look healthier.
But the postmortem autopsy datareveals a stunning twist.
SPEAKER_01 (11:39):
It really is a profound divergence between
clinical symptoms and physicalpathology.
SPEAKER_00 (11:45):
Because nearly a quarter of the thousands of
participants in this studyeventually underwent brain
autopsies after they passedaway.
SPEAKER_01 (11:51):
Right.
SPEAKER_00 (11:52):
And the researchers meticulously measured the
physical hallmarks ofAlzheimer's disease.
They measured the break staging,which you know maps how toxic
tau tangles spread through thebrain's memory centers.
SPEAKER_01 (12:03):
They also measured hippocampal atrophy, which is
the literal shrinkage of thebrain tissue.
SPEAKER_00 (12:08):
And they measured tau levels in the cerebrospinal
fluid.
SPEAKER_01 (12:11):
And across every single one of those physical
metrics, there was zerostatistical difference between
the people who took thecholesterol drugs and the people
who didn't.
SPEAKER_00 (12:18):
Wait, really?
Zero difference.
SPEAKER_01 (12:20):
Zero.
SPEAKER_00 (12:21):
Here's where it gets really interesting, because this
completely fractures thetraditional model of Alzheimer's
we've been taught.
SPEAKER_01 (12:28):
It absolutely does.
SPEAKER_00 (12:29):
You're telling me the patients taking the
medication navigated their dailylives better and retained their
cognitive faculties longer.
But their physical brains werejust as ravaged by tautangles
and tissue loss as the patientswho suffered rapid, severe
dementia.
SPEAKER_01 (12:44):
Yes.
Their brains had the exact samelevel of physical Alzheimer's
disease.
The physical damage wasvirtually identical.
SPEAKER_00 (12:52):
That is wild.
It's like looking at two housesthat endure the exact same
devastating fire.
SPEAKER_01 (12:58):
Oh, that's a good way to picture it.
SPEAKER_00 (12:59):
You know, the structural damage to the wood,
the intense heat, the burntfoundation, it's all identical.
SPEAKER_01 (13:04):
Right.
SPEAKER_00 (13:04):
But somehow, one house stays standing and
habitable for years while theother one instantly collapses
into ash.
SPEAKER_01 (13:10):
Which brings us to the concept of systemic
resilience.
SPEAKER_00 (13:13):
Systemic resilience.
SPEAKER_01 (13:14):
Yes.
The traditional medical modelhas largely viewed Alzheimer's
through a singular lens,assuming that amyloid plaques
and tau tangles directly andexclusively equal memory loss.
Right.
But this autopsy data provesthat the clinical symptoms, the
actual loss of memory and dailyfunction, are not just a strict
one-to-one result of thosephysical tangles.
SPEAKER_00 (13:36):
So the tangles are a prerequisite, but they aren't
the only driver of the decline.
SPEAKER_01 (13:40):
Aaron Powell Exactly.
The physical pathology ofAlzheimer's acts as a massive
stressor, but the speed of thecognitive collapse is heavily
aggravated by other systemicfactors happening throughout the
rest of the body.
SPEAKER_00 (13:51):
Factors that the lipid-lowering drugs are
actively fixing.
SPEAKER_01 (13:55):
Yes, mitigating.
SPEAKER_00 (13:56):
But if the cholesterol drugs aren't
scrubbing the tautangles out ofthe brain directly, how exactly
are they keeping the housestanding?
What is the actual mechanismproviding that resilience?
SPEAKER_01 (14:07):
Well, the study highlights a dual drivers
concept of neurodegeneration.
SPEAKER_00 (14:12):
Dual drivers.
SPEAKER_01 (14:12):
Right.
Lipid lowering regimens,particularly statins, do much
more than just lower numbers ona cholesterol test.
They provide profound vascularstabilization.
SPEAKER_00 (14:21):
Oh, like improving the actual plumbing.
SPEAKER_01 (14:23):
Exactly.
They improve endothelialfunction, which is the health of
the inner lining of your bloodvessels.
SPEAKER_00 (14:28):
Aaron Powell And better blood vessels mean a more
consistent, stable supply ofoxygen and nutrients to the
brain tissue, preventing themicrooschemia that normally
accelerates cognitive decline.
SPEAKER_01 (14:38):
Aaron Powell That's a huge part of it.
But in addition to vascularhealth, these drugs trigger
widespread anti-inflammatoryeffects.
Okay.
And the most critical mechanismdetailed in the study revolves
around cholesterol oxidationproducts.
SPEAKER_00 (14:51):
Aaron Powell Specifically molecules known as
oxysterols, right?
Yes.
Trevor Burrus, Let's focus onthose oxysterols because this
seems to be the linchpin of theentire phenomenon.
SPEAKER_01 (14:58):
Aaron Powell It really is.
When you have high levels ofperipheral cholesterol
circulating in your bloodstream,your body metabolizes some of it
into oxidation products.
SPEAKER_00 (15:08):
Okay.
SPEAKER_01 (15:08):
The two primary ones are 24OHC and 27OHC.
Trevor Burrus, Jr.
SPEAKER_00 (15:12):
So high body cholesterol creates high levels
of Tumel 7OHC in the blood.
SPEAKER_01 (15:17):
Right.
And this raises an importantquestion because the problem
with 27OHC is its molecularstructure.
SPEAKER_00 (15:23):
How so?
SPEAKER_01 (15:24):
Well, unlike standard cholesterol, which is
largely blocked from enteringthe central nervous system,
27OHC has the ability topassively cross the blood-brain
barrier.
SPEAKER_00 (15:34):
Oh, wow.
So it bypasses the brain'ssecurity system entirely.
SPEAKER_01 (15:38):
It really does.
And once 27OHC crosses thatbarrier and enters the brain, it
binds to specific receptors onmicroglia.
SPEAKER_00 (15:45):
Microglia, those are the brain's resident immune
cells, right?
SPEAKER_01 (15:49):
Exactly.
Normally they act as the garbagecollectors, clearing away
cellular debris and keeping theenvironment healthy.
Okay.
But when 27OHC binds to them, itthrows these immune cells into
overdrive.
SPEAKER_00 (16:02):
Ah, so it shifts them from a protective cleanup
crew into a toxic inflammatorystate.
SPEAKER_01 (16:07):
Aaron Powell Yes.
They begin releasinginflammatory cytokines.
And this rampantneuroinflammation acts as an
incredible accelerant for theexisting Alzheimer's pathology.
SPEAKER_00 (16:16):
It's like throwing gasoline on that house fire.
SPEAKER_01 (16:18):
Exactly.
The inflammation chemicallypromotes the rapid accumulation
of toxic beta amyloid.
It creates a hostile, acidicenvironment that makes the
existing tau tangles infinitelymore damaging to the surrounding
neurons.
SPEAKER_00 (16:31):
So wait, let me clarify.
It's not that the statins areacting like a brain scrubber.
They are functioning as a borderpatrol.
SPEAKER_01 (16:36):
That is exactly what they're doing.
SPEAKER_00 (16:38):
So by aggressively lowering the cholesterol
circulating in the body, thedrugs drastically reduce the
production of 27OHC.
SPEAKER_01 (16:46):
Yes.
SPEAKER_00 (16:47):
And with less of that toxic oxystol floating in
the bloodstream, less of itcrosses the blood-brain barrier
to agitate the brain's immunesystem.
SPEAKER_01 (16:54):
They are essentially cutting off the toxic supply
lines.
SPEAKER_00 (16:58):
Wow.
SPEAKER_01 (16:58):
By managing the lipid environment in the
peripheral body, the drugs areliterally starving the
inflammatory process inside thebrain.
SPEAKER_00 (17:06):
Even while the plaques is still there.
SPEAKER_01 (17:08):
Exactly.
The physical plaques entanglesare still forming as the autopsy
showed.
But without that secondary waveof inflammation fueled by 27
OHC, the brain tissue cantolerate the disease burden much
longer.
SPEAKER_00 (17:20):
You know, it reframes our entire
understanding of cognitivepreservation.
SPEAKER_01 (17:24):
It really changes the whole paradigm.
SPEAKER_00 (17:26):
I mean, we started this deep dive exploring a
cross-sectional illusion thatsuggested cholesterol medication
might be harming cognition.
SPEAKER_01 (17:33):
Right, the confounding by indication.
SPEAKER_00 (17:36):
But by shifting to the longitudinal data, we
uncovered a profound protectivebenefit that compounds over a
decade, uniquely tailored by ageand genetics.
Absolutely.
And I think the most revealinginsight for you listening is
that preserving humanindependence doesn't necessarily
require a pristine, undamagedbrain.
SPEAKER_01 (17:54):
No, it doesn't.
SPEAKER_00 (17:55):
Sometimes resilience simply requires cutting off the
biological accelerants that makethe damage catastrophic.
SPEAKER_01 (18:02):
Treating the whole biological system yields
profound neurological benefits,even when the brain itself
cannot be cured.
SPEAKER_00 (18:10):
Right.
SPEAKER_01 (18:10):
But you know, the mechanics of 270HC leave us with
a deeply provocative questionfor the future of medicine.
SPEAKER_00 (18:17):
Oh.
What's that?
SPEAKER_01 (18:19):
Well, we now know that standard cholesterol drugs
dramatically slow cognitivedecline purely by lowering
peripheral cholesterol andpreventing those oxystrols from
crossing the blood-brainbarrier.
Trevor Burrus, Jr.
SPEAKER_00 (18:30):
Right.
They're playing defense from theoutside.
SPEAKER_01 (18:32):
Trevor Burrus, Jr.
Exactly.
So what happens whenpharmaceutical companies
leverage this data to design thenext generation of
lipid-lowering drugs?
SPEAKER_00 (18:40):
Oh, I see where you're going with this.
SPEAKER_01 (18:41):
Yeah.
If a drug were engineeredspecifically to cross the
blood-brain barrier itself,rather than just acting as a
peripheral border patrol, theimplications could be
staggering.
SPEAKER_00 (18:50):
Aaron Powell So directly managing lipid
metabolism and oxysterolproduction inside the brain's
architecture.
SPEAKER_01 (18:57):
Exactly.
Could that be the key to finallyhalting the progression of
Alzheimer's entirely?
SPEAKER_00 (19:03):
That is an incredible thought to leave on.
The medicine cabinet of thefuture might blur the lines
between the cardiovascular andthe neurological entirely.
SPEAKER_01 (19:11):
I think it inevitably will.
SPEAKER_00 (19:13):
Well, thank you for joining us on this deep dive.
We encourage you to keepexploring the brilliant
interconnected complexities ofthe human brain.
So, um when you open your medicine cabinet every
morning, you likely have this,you know, ingrained expectation
of geography.
SPEAKER_01 (00:09):
Aaron Powell Oh, absolutely.
You assume every little bottlehas its own strictly assigned
territory.
SPEAKER_00 (00:13):
Aaron Powell Right.
Like the white pill works onyour heart, the blue one goes to
your lungs, and you know, neverthe twain shall meet.
SPEAKER_01 (00:20):
Yeah, which is a very compartmentalized way of
thinking about human biology.
I mean, it's completelyunderstandable, but it's uh it's
fundamentally inaccurate.
SPEAKER_00 (00:28):
Totally.
SPEAKER_01 (00:29):
Because the body is this immensely complex
interconnected network.
So a drug engineered for onespecific organ is often quietly
remodeling an entirely differentsystem at the exact same time.
SPEAKER_00 (00:40):
Aaron Ross Powell, which is exactly why a
medication millions of peopletake simply to lower their
cholesterol might actually be uma critical key to slowing down
Alzheimer's disease.
SPEAKER_01 (00:50):
Aaron Powell Yeah, it's a fascinating connection.
SPEAKER_00 (00:52):
Aaron Powell So today we're doing a deep dive
for you into a massive new studypublished in 2026 in the Journal
of Prevention of Alzheimer'sdisease.
SPEAKER_01 (00:59):
Right by Sternberg and colleagues.
SPEAKER_00 (01:01):
Aaron Powell Exactly.
And our mission for this deepdive is to bridge that gap.
We want to connect the everydaylipid lowering regimens, you
know, standard statins andcholesterol drugs, with the
actual physical architecture ofthe brain.
SPEAKER_01 (01:14):
Aaron Powell And I think what makes this research
so definitive is the sheer scaleof the data Sternberg's team
utilized.
SPEAKER_00 (01:21):
Oh wow.
Yeah, let's unpack that.
Yeah.
Because they didn't just look ata few hundred people over a
semester or something.
SPEAKER_01 (01:26):
No, not at all.
They pulled records for over28,000 participants from the
National Alzheimer'sCoordinating Center.
SPEAKER_00 (01:32):
Aaron Powell That is massive.
SPEAKER_01 (01:34):
It really is.
And they tracked theseindividuals for up to 15 years.
SPEAKER_00 (01:38):
Aaron Powell A decade and a half of tracking
human lives.
But you know, to get a cleansignal from all that messy data,
they had to be pretty ruthlesswith their filtering, right?
SPEAKER_01 (01:47):
Aaron Ross Powell They were incredibly ruthless.
They ingeniously excluded anyonetaking blood pressure or
diabetes medications.
SPEAKER_00 (01:52):
Aaron Powell Wait, why just those two?
SPEAKER_01 (01:54):
Aaron Powell Well, we know hypertension and insulin
resistance heavily influencecognitive decline on their own.
SPEAKER_00 (01:59):
Aaron Powell Ah, right.
It muddies the waters.
SPEAKER_01 (02:01):
Aaron Ross Powell Exactly.
So by removing participants onthose specific treatments, the
researchers essentially strippedaway the overlapping noise.
SPEAKER_00 (02:09):
Aaron Powell Okay.
So they isolated the exactindependent effect of the
cholesterol drugs to see whatthey were doing on their own.
SPEAKER_01 (02:15):
Aaron Powell That's it.
But you know what's fascinatinghere is that the findings don't
actually start with a triumph.
SPEAKER_00 (02:21):
Aaron Powell No, they really don't.
In fact, if you just glance atthe initial cross-sectional data
like the day zero snapshot ofall these participants, it
creates a pretty alarmingpicture.
Trevor Burrus, Jr.
SPEAKER_01 (02:32):
It does.
It looks terrible at firstglance.
SPEAKER_00 (02:34):
Aaron Powell Because the participants taking the
cholesterol drugs were actuallyscoring worse on cognitive tests
compared to the people nottaking the medication.
SPEAKER_01 (02:42):
Trevor Burrus Right.
The initial data showedsignificantly lower scores on
the MOCA.
SPEAKER_00 (02:46):
That's the Montreal cognitive assessment.
SPEAKER_01 (02:48):
Yes, exactly.
It's used to check short-termmemory and uh visuospatial
abilities.
And they also scored lower onthe MMSE.
SPEAKER_00 (02:55):
Aaron Powell The Mini Mental State Examination.
Trevor Burrus, Jr.
SPEAKER_01 (02:57):
Right, which measures basic orientation and
attention.
SPEAKER_00 (02:59):
Aaron Ross Powell So seeing that on a spreadsheet
immediately triggers a bias.
I mean you see a group of peopletaking a specific pill, and you
see that they have worse memoryscores.
SPEAKER_01 (03:08):
Aaron Powell Yeah.
The instinct is to assume themedication is causing the
decline.
SPEAKER_00 (03:12):
Aaron Powell Wait, so does that mean the medicine
is compromising their cognition?
I mean it's the classic logicalfallacy of walking into a
hospital, seeing rows of sickpeople in beds, and concluding
that the hospital buildingitself is making them sick.
SPEAKER_01 (03:27):
Aaron Powell That's a great analogy.
And that phenomenon is known inepidemiology as confounding by
indication.
SPEAKER_00 (03:33):
Aaron Powell Confounding by Indication.
Okay, break that down for us.
SPEAKER_01 (03:36):
Aaron Ross Powell Well, we have to look at the
underlying reason theseparticipants were prescribed
lipid lowering regimens in thefirst place.
SPEAKER_00 (03:42):
Aaron Powell They got high cholesterol.
SPEAKER_01 (03:43):
Exactly.
They had existing vascularissues.
Their baseline cardiovascularand metabolic risk profiles were
significantly worse than thecontrol group.
SPEAKER_00 (03:52):
Aaron Powell So their underlying biology had
already put them in the dangerzone for cognitive decline long
before the study even started.
SPEAKER_01 (03:58):
Aaron Powell Precisely.
Chronic high cholesterol subtlydamages the microvessels
throughout the body.
And that includes the tiny bloodvessels supplying the brain.
Right.
So the people taking themedication were inherently more
vulnerable to cognitive issuesright from the start.
SPEAKER_00 (04:14):
Aaron Powell So that initial cross-sectional
snapshot, it merely captures thereality that sicker people
require more medication.
SPEAKER_01 (04:21):
Exactly.
To strip away that bias, we haveto look past the snapshot and
analyze the longitudinal dataover time.
You know, the 10-year movie.
SPEAKER_00 (04:30):
Okay, let's unpack that longitudinal data because
the 10-year progressioncompletely flips the script.
SPEAKER_01 (04:35):
It really does.
It's a dramatic shift.
SPEAKER_00 (04:37):
Aaron Powell So the researchers tracked cognitive
and functional decline using theCDR SOB.
That's the clinical dementiarating sum of boxes.
SPEAKER_01 (04:45):
Aaron Powell Right, which is a scoring system that
moves beyond just, you know,standard memory quizzes.
SPEAKER_00 (04:49):
Aaron Powell It measures real-world functional
decline, right?
Things like personal care,community affairs, and problem
solving.
SPEAKER_01 (04:55):
Aaron Powell Yes, exactly.
It's about how someone actuallynavigates their life.
And for participants who startedthe study with mild cognitive
impairment, the users of thecholesterol drugs experienced a
noticeably slower rate ofdecline.
SPEAKER_00 (05:08):
Aaron Powell Okay, but let's look at the actual
numbers.
Because the data showed theiryearly increase on that dementia
severity scale was reduced by0.0088 units compared to
non-users.
SPEAKER_01 (05:21):
Aaron Powell That is what the data showed, yes.
SPEAKER_00 (05:23):
I have to play the skeptic here because
mathematically, point zero zerozero eight eight sounds entirely
negligible.
I mean, why should you or I careabout a fraction of a fraction
of a point?
SPEAKER_01 (05:33):
I get that.
It sounds tiny in a vacuum.
SPEAKER_00 (05:36):
Right.
It's hard to see the practicalvalue.
SPEAKER_01 (05:38):
But chronic neurodegeneration is a game of
inches.
You have to conceptualize thisin the context of a progressive
disease that currently has nodefinitive cure.
Aaron Ross Powell, Jr.
SPEAKER_00 (05:46):
Buying time is the ultimate clinical goal.
SPEAKER_01 (05:49):
Exactly.
Alzheimer's doesn't strip awayindependence overnight.
It's a gradual cascadingfailure.
SPEAKER_00 (05:54):
Aaron Ross Powell So it's the physiological
equivalent of compoundinginterest.
SPEAKER_01 (05:57):
That's a perfect way to look at it.
SPEAKER_00 (05:58):
Like if you shift an interest rate by a fraction of a
percent when you open aretirement account, the
difference year over year isinvisible.
SPEAKER_01 (06:05):
Right.
You don't notice it in year oneor two.
SPEAKER_00 (06:07):
But let that tiny mathematical change compound
over a decade, and it creates amassive divergence in the final
outcome.
SPEAKER_01 (06:15):
Aaron Powell And that divergence is clearly
visible in the transition rates.
So among those with mildcognitive impairment, only 1.48%
of the cholesterol drug userstransitioned into full-blown
dementia per year.
SPEAKER_00 (06:29):
Compared to 1.83% of the non-users.
SPEAKER_01 (06:32):
Yes.
And over 10 years, thatfractional difference compounds
into literally years ofpreserved daily function.
SPEAKER_00 (06:40):
Oh wow.
So it represents the differencebetween an individual managing
their own household versusrequiring institutionalized
round-the-clock care.
SPEAKER_01 (06:49):
Absolutely.
It's the difference betweenliving at home and being in a
nursing facility.
SPEAKER_00 (06:52):
And the protection also held for people already
suffering from advanced stagesof the disease, didn't it?
SPEAKER_01 (06:57):
It did.
For participants who had alreadyprogressed to dementia, the
slowing effect was actually evenmore pronounced.
SPEAKER_00 (07:03):
Wait, really?
Even in late stages?
SPEAKER_01 (07:05):
Yeah.
Over a 10-year window, only0.53% of the lipid-lowering drug
users hit the severe final stageof dementia.
SPEAKER_00 (07:13):
Compared to 1.50% of the non-users, that is a massive
relative difference.
SPEAKER_01 (07:18):
Aaron Powell It's huge.
And over the full 15-yeartracking period, the drug users
simply survived significantlylonger.
SPEAKER_00 (07:24):
Aaron Powell Okay, so we know the drugs by time,
but do they via the same amountof time for everyone?
SPEAKER_01 (07:30):
That is a great question.
And the demographicstratification of this data is
where we find the realmechanical insights.
SPEAKER_00 (07:36):
Aaron Powell Because this protective effect was not
universally distributed acrossthe population.
SPEAKER_01 (07:41):
Rare.
No, it wasn't.
The age breakdown isparticularly fascinating.
Aaron Powell Yeah.
SPEAKER_00 (07:45):
The study showed the protective benefits only emerge
in participants over the age of50.
Trevor Burrus, Jr.
SPEAKER_01 (07:49):
Right.
If a participant was in theirforties, the cholesterol drugs
showed essentially no cognitivebenefit whatsoever.
SPEAKER_00 (07:55):
Trevor Burrus And the protection was strongest for
those over 70.
Trevor Burrus, Jr.
SPEAKER_01 (07:57):
Which aligns perfectly with how cumulative
biological damage works.
I mean, a 40-year-old braingenerally still has robust
vascular defenses andneuroplasticity.
SPEAKER_00 (08:06):
Aaron Powell So the structural damage from poor
lipid metabolism hasn't reacheda critical threshold yet.
SPEAKER_01 (08:12):
Exactly.
But by age 70, the cumulativevascular and metabolic stress is
actively threatening the brain'sdefenses.
SPEAKER_00 (08:19):
So the medication is intervening exactly when the
biological infrastructure beginsto buckle.
SPEAKER_01 (08:24):
You hit the nail on the head.
And then there is a geneticlayer specifically regarding the
APOE4 allele.
SPEAKER_00 (08:30):
Right.
We've long known that carryingthe APOE4 gene is one of the
most significant risk factorsfor developing Alzheimer's.
SPEAKER_01 (08:36):
Yes, it's a major genetic red flag.
SPEAKER_00 (08:38):
And the study found that people with this specific
genetic marker saw highlypronounced outsized benefits
from taking these cholesteroldrugs.
SPEAKER_01 (08:46):
To understand why, we have to look at what APOE4
actually does.
SPEAKER_00 (08:50):
Okay, lay it on this.
SPEAKER_01 (08:51):
So the APOE gene family produces apalipoprotein
E.
This is a protein thattransports fats and cholesterol
throughout the body and thebrain.
Right.
But the E4 variant of this geneis structurally less efficient.
It struggles to clear lipids,leading to cellular stress and
inflammation.
SPEAKER_00 (09:07):
Wait, so the gene most famous for causing
Alzheimer's, it's fundamentallya cholesterol management gene.
SPEAKER_01 (09:12):
Yes, exactly.
If we connect this to the biggerpicture, when a patient with
that faulty E4 gene takes alipid-lowering drug, the
medication is actively reducingthe overall peripheral
cholesterol burden.
SPEAKER_00 (09:25):
Oh, I see.
It is artificially managing thelipid load that the genetic
mutation is failing to handle.
SPEAKER_01 (09:31):
Precisely.
It provides direct support tothe exact biological system, the
APOE4 mutation compromises.
SPEAKER_00 (09:38):
So what does this all mean?
It makes me think of puttingpremium fuel into a car engine.
SPEAKER_01 (09:43):
Oh, I like where this is going.
SPEAKER_00 (09:45):
Like if you have a brand new low-risk engine, say,
a 40-year-old without the APOE4gene paying for premium fuel
doesn't noticeably change howthe car dries.
SPEAKER_01 (09:55):
Right.
The engine is already highlyefficient.
SPEAKER_00 (09:57):
But if the engine is older, or if it has a faulty
fuel injector that causes it torun hot, which is essentially
what the APOE4 gene is doing,suddenly that premium fuel makes
a massive difference inpreventing a breakdown on the
highway.
SPEAKER_01 (10:08):
That is a brilliant analogy.
And taking that car analogy astep further, the researchers
also uncovered distinctmechanical differences based on
gender.
SPEAKER_00 (10:16):
Oh, right.
For the transition phase, movingfrom mild cognitive impairment
into early dementia men sawsignificant protective benefits
from the medication while womendid not.
SPEAKER_01 (10:27):
Yes, but only in that early transition phase.
SPEAKER_00 (10:30):
Because once the disease progressed into the
later stages of dementia, bothmen and women benefited
significantly.
SPEAKER_01 (10:37):
Right.
And we think this is becausehormonal environments uniquely
influence lipid metabolism andvascular health.
SPEAKER_00 (10:44):
Like estrogen.
SPEAKER_01 (10:45):
Exactly.
Estrogen offers distinctneuroprotective and vascular
benefits early on.
This might mask or alter theeffectiveness of the
lipid-lowering drugs in womenduring that initial transition
phase.
SPEAKER_00 (10:56):
Ah, but once those hormonal protections wane or the
disease pathology overwhelmsthem in later stages, the
benefits of the drugs becomeuniversal.
SPEAKER_01 (11:05):
That's exactly what the data suggests.
SPEAKER_00 (11:06):
Okay, so we've established the demographics,
and the data clearly shows thesedrugs are buying people crucial
years of independence.
SPEAKER_01 (11:12):
Yes, they absolutely are.
SPEAKER_00 (11:13):
Which brings us to the most logical assumption.
If these patients are thinkingclearer, functioning better, and
surviving longer, thesecholesterol drugs must be
actively clearing theAlzheimer's pathology out of
their brains.
SPEAKER_01 (11:27):
It is the most logical assumption to make.
You'd think a slower cognitivedecline should equal a cleaner
brain.
SPEAKER_00 (11:33):
We would expect their brains to look healthier.
But the postmortem autopsy datareveals a stunning twist.
SPEAKER_01 (11:39):
It really is a profound divergence between
clinical symptoms and physicalpathology.
SPEAKER_00 (11:45):
Because nearly a quarter of the thousands of
participants in this studyeventually underwent brain
autopsies after they passedaway.
SPEAKER_01 (11:51):
Right.
SPEAKER_00 (11:52):
And the researchers meticulously measured the
physical hallmarks ofAlzheimer's disease.
They measured the break staging,which you know maps how toxic
tau tangles spread through thebrain's memory centers.
SPEAKER_01 (12:03):
They also measured hippocampal atrophy, which is
the literal shrinkage of thebrain tissue.
SPEAKER_00 (12:08):
And they measured tau levels in the cerebrospinal
fluid.
SPEAKER_01 (12:11):
And across every single one of those physical
metrics, there was zerostatistical difference between
the people who took thecholesterol drugs and the people
who didn't.
SPEAKER_00 (12:18):
Wait, really?
Zero difference.
SPEAKER_01 (12:20):
Zero.
SPEAKER_00 (12:21):
Here's where it gets really interesting, because this
completely fractures thetraditional model of Alzheimer's
we've been taught.
SPEAKER_01 (12:28):
It absolutely does.
SPEAKER_00 (12:29):
You're telling me the patients taking the
medication navigated their dailylives better and retained their
cognitive faculties longer.
But their physical brains werejust as ravaged by tautangles
and tissue loss as the patientswho suffered rapid, severe
dementia.
SPEAKER_01 (12:44):
Yes.
Their brains had the exact samelevel of physical Alzheimer's
disease.
The physical damage wasvirtually identical.
SPEAKER_00 (12:52):
That is wild.
It's like looking at two housesthat endure the exact same
devastating fire.
SPEAKER_01 (12:58):
Oh, that's a good way to picture it.
SPEAKER_00 (12:59):
You know, the structural damage to the wood,
the intense heat, the burntfoundation, it's all identical.
SPEAKER_01 (13:04):
Right.
SPEAKER_00 (13:04):
But somehow, one house stays standing and
habitable for years while theother one instantly collapses
into ash.
SPEAKER_01 (13:10):
Which brings us to the concept of systemic
resilience.
SPEAKER_00 (13:13):
Systemic resilience.
SPEAKER_01 (13:14):
Yes.
The traditional medical modelhas largely viewed Alzheimer's
through a singular lens,assuming that amyloid plaques
and tau tangles directly andexclusively equal memory loss.
Right.
But this autopsy data provesthat the clinical symptoms, the
actual loss of memory and dailyfunction, are not just a strict
one-to-one result of thosephysical tangles.
SPEAKER_00 (13:36):
So the tangles are a prerequisite, but they aren't
the only driver of the decline.
SPEAKER_01 (13:40):
Aaron Powell Exactly.
The physical pathology ofAlzheimer's acts as a massive
stressor, but the speed of thecognitive collapse is heavily
aggravated by other systemicfactors happening throughout the
rest of the body.
SPEAKER_00 (13:51):
Factors that the lipid-lowering drugs are
actively fixing.
SPEAKER_01 (13:55):
Yes, mitigating.
SPEAKER_00 (13:56):
But if the cholesterol drugs aren't
scrubbing the tautangles out ofthe brain directly, how exactly
are they keeping the housestanding?
What is the actual mechanismproviding that resilience?
SPEAKER_01 (14:07):
Well, the study highlights a dual drivers
concept of neurodegeneration.
SPEAKER_00 (14:12):
Dual drivers.
SPEAKER_01 (14:12):
Right.
Lipid lowering regimens,particularly statins, do much
more than just lower numbers ona cholesterol test.
They provide profound vascularstabilization.
SPEAKER_00 (14:21):
Oh, like improving the actual plumbing.
SPEAKER_01 (14:23):
Exactly.
They improve endothelialfunction, which is the health of
the inner lining of your bloodvessels.
SPEAKER_00 (14:28):
Aaron Powell And better blood vessels mean a more
consistent, stable supply ofoxygen and nutrients to the
brain tissue, preventing themicrooschemia that normally
accelerates cognitive decline.
SPEAKER_01 (14:38):
Aaron Powell That's a huge part of it.
But in addition to vascularhealth, these drugs trigger
widespread anti-inflammatoryeffects.
Okay.
And the most critical mechanismdetailed in the study revolves
around cholesterol oxidationproducts.
SPEAKER_00 (14:51):
Aaron Powell Specifically molecules known as
oxysterols, right?
Yes.
Trevor Burrus, Let's focus onthose oxysterols because this
seems to be the linchpin of theentire phenomenon.
SPEAKER_01 (14:58):
Aaron Powell It really is.
When you have high levels ofperipheral cholesterol
circulating in your bloodstream,your body metabolizes some of it
into oxidation products.
SPEAKER_00 (15:08):
Okay.
SPEAKER_01 (15:08):
The two primary ones are 24OHC and 27OHC.
Trevor Burrus, Jr.
SPEAKER_00 (15:12):
So high body cholesterol creates high levels
of Tumel 7OHC in the blood.
SPEAKER_01 (15:17):
Right.
And this raises an importantquestion because the problem
with 27OHC is its molecularstructure.
SPEAKER_00 (15:23):
How so?
SPEAKER_01 (15:24):
Well, unlike standard cholesterol, which is
largely blocked from enteringthe central nervous system,
27OHC has the ability topassively cross the blood-brain
barrier.
SPEAKER_00 (15:34):
Oh, wow.
So it bypasses the brain'ssecurity system entirely.
SPEAKER_01 (15:38):
It really does.
And once 27OHC crosses thatbarrier and enters the brain, it
binds to specific receptors onmicroglia.
SPEAKER_00 (15:45):
Microglia, those are the brain's resident immune
cells, right?
SPEAKER_01 (15:49):
Exactly.
Normally they act as the garbagecollectors, clearing away
cellular debris and keeping theenvironment healthy.
Okay.
But when 27OHC binds to them, itthrows these immune cells into
overdrive.
SPEAKER_00 (16:02):
Ah, so it shifts them from a protective cleanup
crew into a toxic inflammatorystate.
SPEAKER_01 (16:07):
Aaron Powell Yes.
They begin releasinginflammatory cytokines.
And this rampantneuroinflammation acts as an
incredible accelerant for theexisting Alzheimer's pathology.
SPEAKER_00 (16:16):
It's like throwing gasoline on that house fire.
SPEAKER_01 (16:18):
Exactly.
The inflammation chemicallypromotes the rapid accumulation
of toxic beta amyloid.
It creates a hostile, acidicenvironment that makes the
existing tau tangles infinitelymore damaging to the surrounding
neurons.
SPEAKER_00 (16:31):
So wait, let me clarify.
It's not that the statins areacting like a brain scrubber.
They are functioning as a borderpatrol.
SPEAKER_01 (16:36):
That is exactly what they're doing.
SPEAKER_00 (16:38):
So by aggressively lowering the cholesterol
circulating in the body, thedrugs drastically reduce the
production of 27OHC.
SPEAKER_01 (16:46):
Yes.
SPEAKER_00 (16:47):
And with less of that toxic oxystol floating in
the bloodstream, less of itcrosses the blood-brain barrier
to agitate the brain's immunesystem.
SPEAKER_01 (16:54):
They are essentially cutting off the toxic supply
lines.
SPEAKER_00 (16:58):
Wow.
SPEAKER_01 (16:58):
By managing the lipid environment in the
peripheral body, the drugs areliterally starving the
inflammatory process inside thebrain.
SPEAKER_00 (17:06):
Even while the plaques is still there.
SPEAKER_01 (17:08):
Exactly.
The physical plaques entanglesare still forming as the autopsy
showed.
But without that secondary waveof inflammation fueled by 27
OHC, the brain tissue cantolerate the disease burden much
longer.
SPEAKER_00 (17:20):
You know, it reframes our entire
understanding of cognitivepreservation.
SPEAKER_01 (17:24):
It really changes the whole paradigm.
SPEAKER_00 (17:26):
I mean, we started this deep dive exploring a
cross-sectional illusion thatsuggested cholesterol medication
might be harming cognition.
SPEAKER_01 (17:33):
Right, the confounding by indication.
SPEAKER_00 (17:36):
But by shifting to the longitudinal data, we
uncovered a profound protectivebenefit that compounds over a
decade, uniquely tailored by ageand genetics.
Absolutely.
And I think the most revealinginsight for you listening is
that preserving humanindependence doesn't necessarily
require a pristine, undamagedbrain.
SPEAKER_01 (17:54):
No, it doesn't.
SPEAKER_00 (17:55):
Sometimes resilience simply requires cutting off the
biological accelerants that makethe damage catastrophic.
SPEAKER_01 (18:02):
Treating the whole biological system yields
profound neurological benefits,even when the brain itself
cannot be cured.
SPEAKER_00 (18:10):
Right.
SPEAKER_01 (18:10):
But you know, the mechanics of 270HC leave us with
a deeply provocative questionfor the future of medicine.
SPEAKER_00 (18:17):
Oh.
What's that?
SPEAKER_01 (18:19):
Well, we now know that standard cholesterol drugs
dramatically slow cognitivedecline purely by lowering
peripheral cholesterol andpreventing those oxystrols from
crossing the blood-brainbarrier.
Trevor Burrus, Jr.
SPEAKER_00 (18:30):
Right.
They're playing defense from theoutside.
SPEAKER_01 (18:32):
Trevor Burrus, Jr.
Exactly.
So what happens whenpharmaceutical companies
leverage this data to design thenext generation of
lipid-lowering drugs?
SPEAKER_00 (18:40):
Oh, I see where you're going with this.
SPEAKER_01 (18:41):
Yeah.
If a drug were engineeredspecifically to cross the
blood-brain barrier itself,rather than just acting as a
peripheral border patrol, theimplications could be
staggering.
SPEAKER_00 (18:50):
Aaron Powell So directly managing lipid
metabolism and oxysterolproduction inside the brain's
architecture.
SPEAKER_01 (18:57):
Exactly.
Could that be the key to finallyhalting the progression of
Alzheimer's entirely?
SPEAKER_00 (19:03):
That is an incredible thought to leave on.
The medicine cabinet of thefuture might blur the lines
between the cardiovascular andthe neurological entirely.
SPEAKER_01 (19:11):
I think it inevitably will.
SPEAKER_00 (19:13):
Well, thank you for joining us on this deep dive.
We encourage you to keepexploring the brilliant
interconnected complexities ofthe human brain.
Popular Podcasts
Hey Jonas!
Hey Jonas! The official Jonas Brothers podcast. Hosted by Kevin, Joe, and Nick Jonas. It’s the Jonas Brothers you know... musicians, actors, and well, yes, brothers. Now, they’re sharing another side of themselves in the playful, intimate, and irreverent way only they can. Spend time with the Jonas Brothers here and stay a little bit longer for deep conversations like never before.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com